Leveraging our multi specific antibody platform to target and modulate the tumor microenvironment to enhance or re-activate anti-tumor immune response.
Program
Indications
Preclinical
IND-Enabling
Phase I
Phase II
QL325 AML Targeted T Cell Engager
Acute Myeloid Leukemia
QL335 CRC Targeted T Cell Engager
Colorectal Cancer
QL401 PD-L1 x 4-1BB
T Cell Stimulation

No Stimulation

A bispecific antibody targeting PD-L1-positive tumors stimulates T cell via 4-1BB
QL301 activates 4-1BB only when concurrently engaged to PD-L1, an immune checkpoint mediator elevated in the immuno-suppressive tumor microenvironment. Unwanted toxicity associated with non-specific activation of 4-1BB is therefore minimized. QL301 blocks the interaction of PD-1 with PD-L1 independent of 4-1BB binding. The combination of 4-1BB activation and PD-L1 blockade promotes a robust and lasting anti-tumor immune response. QL301 was well tolerated in a toxicology study. A phase 1 clinical trial is ongoing.
View poster presented at the AACR Annual Meeting 2022.
QL401 PD-L1 x CD47
High Avidity Binding

Minimal Binding
